EXEL vs. TECH: Exelixis vs. Bio-Techne Stock Comparison

November 11, 2026

How do Exelixis (EXEL) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Company profile comparison for Exelixis (EXEL) and Bio-Techne (TECH)
Profile Item	EXEL	TECH
Name	Exelixis Inc.	Bio-Techne Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	16.98 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	April 17, 2000	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

EXEL

TECH

GSPC

Exelixis (EXEL) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Exelixis (EXEL) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Exelixis (EXEL) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
Total Return (1Y)	74.98%	27.56%
Total Return (3Y, Annualized)	50.33%	9.11%
Total Return (5Y, Annualized)	31.10%	-9.91%

Risk Profile

Drawdown History

EXEL

TECH

GSPC

Exelixis (EXEL) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Exelixis (EXEL) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
Volatility (1Y, Annualized)	34.17%	43.08%
Beta (5Y)	0.41	1.26
Max Drawdown (5Y)	-35.41%	-65.87%
Avg. Volume (3M)	2.33M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

EXEL and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
Sharpe Ratio (1Y)	2.07	0.54
Sortino Ratio (1Y)	3.23	0.82

Profitability

ROE (TTM)

Both Exelixis (EXEL) at 44.32% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max: 109.18%
EXEL: 44.32%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL: 35.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Exelixis (EXEL) at 40.75% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max: 83.12%
EXEL: 40.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
ROE (TTM)	44.32%	8.33%
ROA (TTM)	23.52%	6.38%
Net Margin (TTM)	35.45%	14.00%
Operating Margin (TTM)	40.75%	12.21%
Gross Margin (TTM)	96.26%	66.23%

Growth

Revenue Growth

Both Exelixis (EXEL) at 6.98% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Exelixis (EXEL) at 57.95% is closer to the peer norm — faster per-share earnings growth for TECH.

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
Revenue Growth (YoY)	6.98%	-0.38%
Revenue Growth (3Y CAGR)	12.93%	2.25%
EPS Growth (YoY)	57.95%	152.17%
EPS Growth (3Y CAGR)	70.59%	-12.97%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Bio-Techne (TECH) at 2.28 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TECH.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max: 25.13
Q3: 12.13
Median: 5.52
EXEL: 3.21
Q1: 2.47
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Exelixis (EXEL) at 0.09 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
EXEL: 0.09
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
Current Ratio (MRQ)	3.21	2.28
Debt / Equity (MRQ)	0.09	0.13
Net Debt / EBITDA	-0.71	-0.20

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Exelixis (EXEL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
Dividend Yield (TTM)	0.00%	0.44%
Dividend Payout Ratio (TTM)	0.00%	27.59%

Valuation

P/E Ratio (TTM)

Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max: 85.34
Q3: 43.46
Median: 26.69
EXEL: 20.83
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Exelixis (EXEL) at 6.80 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max: 58.18
Q3: 25.77
Median: 7.30
EXEL: 6.80
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Techne (TECH) at 5.28 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max: 13.53
EXEL: 9.28
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

Exelixis (EXEL) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and Bio-Techne (TECH)
Metric	EXEL	TECH
P/E Ratio (TTM)	20.83	62.74
P/S Ratio (TTM)	6.80	9.31
P/B Ratio (MRQ)	9.28	5.28
Free Cash Flow Yield (TTM)	4.47%	2.39%